Endoscopic features and prognoses of mantle cell lymphoma with gastrointestinal involvement

被引:32
作者
Iwamuro, Masaya [1 ]
Okada, Hiroyuki [1 ]
Kawahara, Yoshiro [1 ]
Shinagawa, Katsuji [2 ]
Morito, Toshiaki [3 ]
Yoshino, Tadashi [3 ]
Yamamoto, Kazuhide [1 ]
机构
[1] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol & Hepatol, Kita Ku, Okayama 7008558, Japan
[2] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Hematol & Oncol, Okayama 7008558, Japan
[3] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Pathol, Okayama 7008558, Japan
关键词
Chemotherapy; Gastrointestinal lymphoma; Mantle cell lymphoma; Multiple lymphomatous polyposis; Non-Hodgkin's lymphoma; PROSPECTIVE RANDOMIZED-TRIAL; NON-HODGKINS-LYMPHOMAS; EUROPEAN-MCL-NETWORK; HYPER-CVAD; RESPONSE CRITERIA; IMPROVES RESPONSE; TISSUE LYMPHOMA; MALT LYMPHOMA; FREE SURVIVAL; RITUXIMAB;
D O I
10.3748/wjg.v16.i37.4661
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: To evaluate the endoscopic manifestations and prognoses of gastrointestinal (GI) mantle cell lymphoma (MCL). METHODS: A database search at the Department of Pathology of Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences revealed 57 MCL patients with GI involvement. Clinical records were available for 35 of the 57 patients from 21 institutions, and those 35 patients were enrolled in this study. We summarized the gross types of endoscopic features, event-free survival (EFS), and overall survival (OS) of those patients. RESULTS: Of the 35 patients, GI involvement in the esophagus, stomach, and duodenum was found in 2 (5.7%), 26 (74.3%), and 12 (34.3%) patients, respectively. Twenty-one of the 35 patients underwent colonoscopy; among them, GI involvement in the ileum, cecum, colon, and rectum was found in 10 (47.6%), 3 (14.3%), 12 (57.1%), and 10 (47.6%), respectively. Various lesions, such as superficial, protruded, fold thickening, or ulcerative, were found in the stomach, whereas multiple lymphomatous polyposis (MLP) was dominant from the duodenum to the rectum. Twelve patients were treated with a hyper-CVAD/MA regimen, and they had better OS (3-year rate, 88.3% vs 46.4%, P < 0.01) and better EFS (3-year rate, 66.7% vs 33.8%, P < 0.05) than the remaining 23 patients who were not treated with this regimen. CONCLUSION: MLP was a representative form of intestinal involvement, whereas a variety of lesions were found in the stomach. The hyper-CVAD/MA regimen may improve survival in these patients. (C) 2010 Baishideng. All rights reserved.
引用
收藏
页码:4661 / 4669
页数:9
相关论文
共 37 条
  • [1] [Anonymous], 1993, N ENGL J MED, V329, P987
  • [2] Diagnosis, treatment decisions, and follow up in primary gastric lymphoma
    Boot, H
    de Jong, D
    [J]. GUT, 2002, 51 (05) : 621 - 622
  • [3] Bosch F, 1998, CANCER, V82, P567, DOI 10.1002/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO
  • [4] 2-Z
  • [5] Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas
    Cheson, BD
    Horning, SJ
    Coiffier, B
    Shipp, MA
    Fisher, RI
    Connors, JM
    Lister, TA
    Vose, J
    Grillo-López, A
    Hagenbeek, A
    Cabanillas, F
    Klippensten, D
    Hiddemann, W
    Castellino, R
    Harris, NL
    Armitage, JO
    Carter, W
    Hoppe, R
    Canellos, GP
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) : 1244 - 1253
  • [6] COMES JS, 1961, CANCER, V14, P249
  • [7] PRIMARY MALIGNANT LYMPHOID TUMOURS OF THE INTESTINAL TRACT - REPORT OF 37 CASES WITH A STUDY OF FACTORS INFLUENCING PROGNOSIS
    DAWSON, IMP
    CORNES, JS
    MORSON, BC
    [J]. BRITISH JOURNAL OF SURGERY, 1961, 49 (213) : 80 - 89
  • [8] Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade lymphoma Study Group
    Determann, Olaf
    Hoster, Eva
    Ott, German
    Bernd, Heinz Wolfram
    Loddenkemper, Christoph
    Hansmann, Martin Leo
    Barth, Thomas E. F.
    Unterhalt, Michael
    Hiddemann, Wolfgang
    Dreyling, Martin
    Klapper, Wolfram
    [J]. BLOOD, 2008, 111 (04) : 2385 - 2387
  • [9] FRAGA M, 1995, HISTOPATHOLOGY, V26, P413
  • [10] How I treat mantle cell lymphoma
    Ghielmini, Michele
    Zucca, Emanuele
    [J]. BLOOD, 2009, 114 (08) : 1469 - 1476